All articles by GlobalData Healthcare

ESMO26: Iza-bren leads post-TKI ADCs on efficacy, but toxicity could decide

On 26 October 2026, Li Zhang presented the Phase III PANKU-Lung01 trial at the European Society for Medical Oncology (ESMO)…
IDWeek 2026: BNT163 poised to fulfil a substantial unmet need for genital herpes

At the 15th annual IDWeek conference in Washington DC, Federico Mensa of BioNTech presented data on BNT163, a trivalent mRNA…
ESMO26: Intismeran sets new benchmark in adjuvant melanoma

At the 2026 European Society for Medical Oncology (ESMO) Congress, full results from Merck and Moderna’s Phase III INTerpath-001 trial…
IDWeek 2026: meropenem-pilabactam successfully targets critical priority pathogens

At the 15th annual IDWeek conference in Washington DC, Rienk Pypstra, MD, chief medical officer of Antabio, presented data on…
ESMO26: Promising results seen for opamtistomig in advanced heavily treated epNEC

At the European Society for Medical Oncology (ESMO) Congress 2026, results were presented from the pivotal, registrational Phase IIb study…

ESMO26: Sac-TMT’s OptiTROP-Lung04 survival gain holds, putting the onus on MSD

On 25 October 2026, Professor Wenfeng Fang presented the final overall survival (OS) analysis of the Phase III OptiTROP-Lung04 trial…
IDWeek 2026: novel antifungal turletricin demonstrates positive Phase II results

At the 15th annual IDWeek conference in Washington DC, Elion Therapeutics, working alongside Mbarara University of Science and Technology, the…
IDWeek 2026: olorofim shows promise in second-line invasive aspergillosis

At the IDWeek 2026 conference in Washington, DC, F2G's chief medical officer John Rex presented data from a Phase III…
ESMO26: Amgen’s Imdelltra posts win in first-line SCLC maintenance setting

On 24 October, 2026, Jacob Sands of Dana-Farber Cancer Institute presented the primary analysis of the Phase III DeLLphi-305 trial…
ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer

In 2023, Bristol Myers Squibb entered an $8.4bn licensing agreement with Chinese biotech SystImmune for izalontamab brengitecan, or iza-bren, an…